Papapetropoulos Spyros 4
4 · Neuphoria Therapeutics Inc. · Filed Apr 18, 2025
Insider Transaction Report
Form 4
Papapetropoulos Spyros
DirectorPresident and CEO
Transactions
- Award
Employee Stock Option (Right-to-Buy)
2025-04-16$5.16/sh+270,000$1,393,200→ 282,529 totalExercise: $5.16Exp: 2035-04-16→ Common Stock (270,000 underlying)
Footnotes (1)
- [F1]Subject to the Reporting Person's continuing service with the Company, the options shall vest on a monthly basis over a three-year period at the rate of 2.78% of the shares of Common Stock on the last day of each month following September 1, 2024 until the options are vested.